A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 807 participants.
Also called NCT01126580
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 807 participants
- Sponsor
- Registry
-
NCT01126580 -
CTRI/2010/091/003036
-
- Other papers using this trial's data
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Canada, Croatia, Czechia, Finland, France, Germany, India, Mexico, Poland, Puerto Rico, Romania, Slovakia, South Africa, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01126580. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2015-01-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- LY2189265
- Intervention (Drug)
- Placebo (oral)
- Intervention (Drug)
- Placebo (subcutaneous)
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01126580- Content hash
65d1806a8ede96d5d2ff443e285e3dce3ec6268801f682fce9f179f815f9ea2e